ArticleScientific reports2019
Diffusion-Weighted Magnetic Resonance Imaging of Patients with Breast Cancer Following Neoadjuvant Chemotherapy Provides Early Prediction of Pathological Response - A Prospective Study.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Pretreatment apparent diffusion coefficient does not predict therapy response to neoadjuvant chemotherapy in breast cancer.Breast (Edinburgh, Scotland) · 2020Pooled it
- Pretreatment Ki67-to-ADC Ratio Predicts Prognosis in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: A Retrospective Cohort Study.Current oncology (Toronto, Ont.) · 2026Article
- Comparison of [European journal of nuclear medicine and molecular imaging · 2026Article
- Automated Apparent Diffusion Coefficient Measurement of Breast Tumors in Diffusion-weighted MRI for Early Neoadjuvant Chemotherapy Response Assessment.Radiology. Imaging cancer · 2026Article
- Multimodal imaging and artificial intelligence for response assessment to neoadjuvant therapy in breast cancer: a comprehensive review.NPJ breast cancer · 2026Review
- Image Quality Assessment of Diffusion-Weighted Imaging (DWI) and Its Impact on Apparent Diffusion Coefficient (ADC) as a Quantitative Imaging Biomarker for Predicting Response to Neoadjuvant Chemotherapy in High-Risk Early Breast Cancer.Tomography (Ann Arbor, Mich.) · 2026Article
- Diagnostic performance of MRI in predicting pathological response in patients with triple-negative breast carcinomas undergoing neoadjuvant chemotherapy and immunotherapy.European radiology · 2026Article
- Modification of RECIST 1.1 criteria for assessing response in breast tumours treated with radiation therapy using multiparametric breast MRI: Radiology and oncology perspective.Breast (Edinburgh, Scotland) · 2026Article
- Apparent diffusion coefficient and intravoxel incoherent motion-derived true diffusion serve as early non-contrast longitudinal biomarkers of neoadjuvant chemotherapy response.Scientific reports · 2026Article
- Time-Dependent DCE-MRI Radiomics to Predict Response to Neoadjuvant Therapy in Breast Cancer: A Multicenter Study with External Validation.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Tumor shrinkage patterns and optimal timing of response assessment during neoadjuvant therapy for breast cancer: a study based on multiparametric MRI.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Percentage apparent diffusion coefficient change for early prediction of response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis, and a retrospective study.Quantitative imaging in medicine and surgery · 2025Article
- Breast Diffusion-weighted MR Imaging: Current Applications, Insights from Screening, and Future Directions.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2025Review
- Diffusion-weighted MRI-Derived ADC and tumor volume as predictive imaging markers for neoadjuvant chemotherapy response in muscle-invasive bladder cancer.BMC medical imaging · 2025Article
- Advances in breast cancer diagnosis: a comprehensive review of imaging, biosensors, and emerging wearable technologies.Frontiers in oncology · 2025Review
- Assessment of the efficacy of various neoadjuvant anti-HER2 targeted therapies combined with chemotherapy for HER2-positive breast cancer in the real-world setting and development of a predictive model for pathological complete response.Frontiers in oncology · 2025Article
- Longitudinal ultrasound-based AI model predicts axillary lymph node response to neoadjuvant chemotherapy in breast cancer: a multicenter study.European radiology · 2024Article
- A non-invasive artificial intelligence model for identifying axillary pathological complete response to neoadjuvant chemotherapy in breast cancer: a secondary analysis to multicenter clinical trial.British journal of cancer · 2024Article
- Update on DWI for Breast Cancer Diagnosis and Treatment Monitoring.AJR. American journal of roentgenology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
The purpose of this study was to evaluate the capacity of diffusion-weighted magnetic resonance imaging (DW-MRI) for early prediction of pathological response in breast cancer patients undergoing neoadjuvant chemotherapy (NCT). This prospective unicentric study evaluated 62 patients who underwent NCT. MRI was performed prior to the start of treatment (MR1), after the first NCT cycle (MR2), and upon completion of NCT (MR3). Pathological response was used as the gold-standard. Patients' median age was 45.5 years and the median tumor size was 40 mm. Twenty-four (38.7%) tumors presented complete pathological response (pCR). The percent increase in apparent diffusion coefficient (ADC) value between MR1 and MR2 was higher in the pCR group (p < 0.001). When the minimum increase in ADC between MR1 and MR2 was set at 25%, sensitivity was 83%, specificity was 84%, positive predictive value was 77%, negative predictive value was 89%, and accuracy was 84% for an early prediction of pCR to NCT. Meanwhile, there were no significant changes in major tumor dimensions between MR1 and MR2. In conclusion, an increase in ADC after the first cycle of NCT correlates well with pCR after the chemotherapy in our cohort, precedes reduction in tumor size on conventional MRI, and may therefore be used as an early predictor of treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.